1
|
La Barbera L, Rizzo C, Camarda F, Atzeni F, Miceli G, Molica Colella AB, Franchina V, Giardina A, Corrao S, Provenzano G, Bursi R, Foti R, Dal Bosco Y, Debilio C, Luppino F, Colaci M, Aprile ML, Bentivegna M, Cassarà E, Lo Gullo A, De Andres MI, Guggino G. Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience. Clin Exp Rheumatol 2024; 42:991-998. [PMID: 38197190 DOI: 10.55563/clinexprheumatol/k78ug3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 10/25/2023] [Indexed: 01/11/2024]
Abstract
OBJECTIVES We investigated the effectiveness and safety of filgotinib in a real-life multicentre cohort of rheumatoid arthritis (RA) patients. METHODS RA patients were evaluated at baseline and after 12 and 24 weeks and were stratified based on previous treatments as biologic disease-modifying anti-rheumatic drug (bDMARD)-naive and bDMARD-insufficient responders (IR). Concomitant usage of methotrexate (MTX) and oral glucocorticoids (GC) was recorded. At each timepoint we recorded disease activity, laboratory parameters and adverse events. RESULTS 126 patients were enrolled. 15.8% were bDMARD-naive (G0), while 84% were bDMARD-IR (G1). In G0, 45% of patients were in monotherapy (G2) and 55% were taken MTX (G3). In G1, 50% of patients were in monotherapy (G4) and 50% used MTX (G5).A significant reduction in all parameters at 12 weeks was observed; in the extension to 24 weeks the significant reduction was maintained for patient global assessment (PGA), examiner global assessment (EGA), visual analogue scale (VAS) pain, VAS fatigue, disease activity score (DAS)28- C-reactive protein (CRP) and CRP values. Filgotinib in monotherapy showed better outcomes in bDMARD-naive patients, with significant differences for patient reported outcomes (PROs) and DAS28-CRP. At 12 weeks, low disease activity (LDA) and remission were achieved in a percentage of 37.2 % and 10.7 % by simplified disease activity index (SDAI), 42.6 % and 5.7 % by clinical disease activity index (CDAI), 26.8 % and 25.2 % by DAS28-CRP, respectively. A significant decrease in steroid dose was evidenced in all patients. We observed a major adverse cardiovascular event in one patient and an increase in transaminase in another. No infections from Herpes Zoster were reported. CONCLUSIONS Our real-world data confirm the effectiveness and safety of filgotinib in the management of RA, especially in bDMARD-naive patients.
Collapse
Affiliation(s)
- Lidia La Barbera
- Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy
| | - Chiara Rizzo
- Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy
| | - Federica Camarda
- Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy
| | - Fabiola Atzeni
- Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Italy
| | - Giovanni Miceli
- Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Italy
| | | | | | - Annarita Giardina
- Internal Medicine Department iGR, National Relevance Hospital Trust, ARNAS Civico, Di Cristina e Benfratelli, Palermo, Italy
| | - Salvatore Corrao
- Internal Medicine Department iGR, National Relevance Hospital Trust, ARNAS Civico, Di Cristina e Benfratelli, Palermo, Italy
| | | | - Roberto Bursi
- Rheumatology Unit, Villa Sofia-Cervello Hospital, Palermo, Italy
| | - Rosario Foti
- Rheumatology Unit, Vittorio-Emanuele Hospital, Catania, Italy
| | | | - Carmelo Debilio
- Rheumatology Unit, Department of Medicine, Sant'Antonio Abate Hospital, Trapani, Italy
| | - Flavia Luppino
- Rheumatology Unit, Department of Medicine, Sant'Antonio Abate Hospital, Trapani, Italy
| | - Michele Colaci
- Unit of Internal Medicine and Hypertension Centre, Department of Clinical and Experimental Medicine, University of Catania, Cannizzaro Hospital, Catania, Italy
| | - Maria Letizia Aprile
- Unit of Internal Medicine and Hypertension Centre, Department of Clinical and Experimental Medicine, University of Catania, Cannizzaro Hospital, Catania, Italy
| | - Mario Bentivegna
- Integrated Reference Centre of Rheumatology, ASP 7, Scicli Hospital, Ragusa, Italy
| | - Emanuele Cassarà
- Integrated Reference Centre of Rheumatology, ASP 7, Scicli Hospital, Ragusa, Italy
| | - Alberto Lo Gullo
- Unit of Rheumatology, Department of Medicine, ARNAS Garibaldi Hospital, Catania, Italy
| | | | - Giuliana Guggino
- Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy.
| |
Collapse
|
2
|
Colaci M, Zanoli L, La Malfa L, Caruso R, De Andres MI, Sambataro D, Sambataro G, Castellino P, Malatino L. Reduction of carotid baroreceptor sensitivity in systemic sclerosis. Clin Exp Rheumatol 2022; 40:1964-1969. [DOI: 10.55563/clinexprheumatol/4j6028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Accepted: 04/29/2022] [Indexed: 11/13/2022]
Affiliation(s)
- Michele Colaci
- Rheumatology Clinic, Internal Medicine Unit, AOE Cannizzaro, Catania, and Department of Clinical and Experimental Medicine, University of Catania, Italy.
| | - Luca Zanoli
- Internal Medicine Unit, AOUP G. Rodolico-S. Marco, Catania, and Department of Clinical and Experimental Medicine, University of Catania, Italy
| | - Lara La Malfa
- Rheumatology Clinic, Internal Medicine Unit, AOE Cannizzaro, Catania, Italy
| | - Rossella Caruso
- Rheumatology Clinic, Internal Medicine Unit, AOE Cannizzaro, Catania, Italy
| | | | - Domenico Sambataro
- Department of Clinical and Experimental Medicine, University of Catania, Italy
| | - Gianluca Sambataro
- Department of Clinical and Experimental Medicine, University of Catania, Italy
| | - Pietro Castellino
- Internal Medicine Unit, AOUP G. Rodolico-S. Marco, Catania, and Department of Clinical and Experimental Medicine, University of Catania, Italy
| | - Lorenzo Malatino
- Rheumatology Clinic, Internal Medicine Unit, AOE Cannizzaro, Catania, and Department of Clinical and Experimental Medicine, University of Catania, Italy
| |
Collapse
|